Ranibizumab for Diabetic Retinopathy

(4 PORT Trial)

This trial tests a treatment called ranibizumab for individuals with proliferative diabetic retinopathy, a severe diabetic eye disease, who experience eye bleeding requiring surgery. The study aims to determine if a medication-filled implant (PDS Implant filled with 100 mg/mL Ranibizumab) can improve outcomes when combined with limited laser treatment during surgery. It is open to those who have diabetic eye disease, need specific eye surgery, and have received at least two prior injections for their condition. The goal is to evaluate the safety and effectiveness of this combined treatment approach. As a Phase 4 trial, this research focuses on understanding how the already FDA-approved and effective treatment can benefit more patients.

Research has shown that the Port Delivery System (PDS) with ranibizumab, studied for diabetic retinopathy, is generally well-tolerated by patients. In one study, 27.5% of participants with the PDS implant experienced side effects, compared to 8.9% of those receiving monthly ranibizumab injections. However, these side effects were not severe, and any vision changes resolved within a few weeks.

Ranibizumab is unique because it targets a specific pathway involved in diabetic retinopathy by inhibiting vascular endothelial growth factor (VEGF), which contributes to abnormal blood vessel growth and leakage in the eye. Unlike traditional treatments like laser photocoagulation, which can cause damage to surrounding retinal tissue, ranibizumab offers a more focused approach with potentially fewer side effects. Researchers are excited about this treatment because it may provide a safer and more effective alternative to manage diabetic retinopathy, especially in cases requiring surgery, by integrating seamlessly into existing procedures and reducing complications.

Research has shown that ranibizumab, delivered through a Port Delivery System (PDS), offers promising results for eye conditions related to diabetes. Studies have found that this method can improve vision as effectively as monthly injections for patients with diabetic macular edema (DME), a condition linked to diabetic retinopathy. In this trial, participants will receive the PDS with ranibizumab during vitrectomy to evaluate its safety and efficacy. The PDS provides a continuous supply of the medication, offering a more convenient and less invasive alternative to frequent injections. The treatment has improved vision without major side effects for most people, though some have reported minor issues like eye irritation. Overall, evidence supports ranibizumab's potential effectiveness for treating diabetic retinopathy, even in cases with eye bleeding.¹²⁴⁶⁷